These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 18156144)

  • 1. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
    Castagneto B; Botta M; Aitini E; Spigno F; Degiovanni D; Alabiso O; Serra M; Muzio A; Carbone R; Buosi R; Galbusera V; Piccolini E; Giaretto L; Rebella L; Mencoboni M
    Ann Oncol; 2008 Feb; 19(2):370-3. PubMed ID: 18156144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
    J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
    Hughes A; Calvert P; Azzabi A; Plummer R; Johnson R; Rusthoven J; Griffin M; Fishwick K; Boddy AV; Verrill M; Calvert H
    J Clin Oncol; 2002 Aug; 20(16):3533-44. PubMed ID: 12177114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
    Vogelzang NJ; Rusthoven JJ; Symanowski J; Denham C; Kaukel E; Ruffie P; Gatzemeier U; Boyer M; Emri S; Manegold C; Niyikiza C; Paoletti P
    J Clin Oncol; 2003 Jul; 21(14):2636-44. PubMed ID: 12860938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Favaretto AG; Grossi F; Bidoli P; Del Conte G; Ceribelli A; Bearz A; Morenghi E; Cavina R; Marangolo M; Parra HJ; Santoro A
    J Clin Oncol; 2006 Mar; 24(9):1443-8. PubMed ID: 16549838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
    Santoro A; O'Brien ME; Stahel RA; Nackaerts K; Baas P; Karthaus M; Eberhardt W; Paz-Ares L; Sundstrom S; Liu Y; Ripoche V; Blatter J; Visseren-Grul CM; Manegold C
    J Thorac Oncol; 2008 Jul; 3(7):756-63. PubMed ID: 18594322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
    Katirtzoglou N; Gkiozos I; Makrilia N; Tsaroucha E; Rapti A; Stratakos G; Fountzilas G; Syrigos KN
    Clin Lung Cancer; 2010 Jan; 11(1):30-5. PubMed ID: 20085865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.
    van den Bogaert DP; Pouw EM; van Wijhe G; Vernhout RM; Surmont VF; Hoogsteden HC; van Klaveren RJ
    J Thorac Oncol; 2006 Jan; 1(1):25-30. PubMed ID: 17409823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Mencoboni M; Botta M; Grossi F; Cortinovis D; Zilembo N; Ripa C; Tiseo M; Favaretto AG; Soto-Parra H; De Vincenzo F; Bruzzone A; Lorenzi E; Gianoncelli L; Ercoli B; Giordano L; Santoro A
    Br J Cancer; 2013 Aug; 109(3):552-8. PubMed ID: 23860535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
    Pasello G; Nicotra S; Marulli G; Rea F; Bonanno L; Carli P; Magro C; Jirillo A; Favaretto A
    Lung Cancer; 2011 Sep; 73(3):351-5. PubMed ID: 21296448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
    Taylor P; Castagneto B; Dark G; Marangolo M; Scagliotti GV; van Klaveren RJ; Labianca R; Serke M; Schuette W; van Meerbeeck JP; Heigener D; Liu Y; Adachi S; Blatter J; von Pawel J
    J Thorac Oncol; 2008 Jul; 3(7):764-71. PubMed ID: 18594323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?
    Li L; Razak AR; Hughes A
    Lung Cancer; 2009 May; 64(2):207-10. PubMed ID: 18926592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA; Ceresoli GL; Garassino I; De Vincenzo F; Cavina R; Campagnoli E; Cappuzzo F; Salamina S; Soto Parra HJ; Santoro A
    Cancer; 2008 Apr; 112(7):1555-61. PubMed ID: 18286536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA; Perrino M; Lorenzi E; Ceresoli GL; De Vincenzo F; Simonelli M; Gianoncelli L; De Sanctis R; Giordano L; Santoro A
    Lung Cancer; 2014 Jun; 84(3):265-70. PubMed ID: 24321581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.
    Berardi R; Caramanti M; Fiordoliva I; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Castagnani M; Rovinelli F; Onofri A; Cascinu S
    Support Care Cancer; 2015 Mar; 23(3):621-6. PubMed ID: 25142706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with Carboplatin and pemetrexed.
    Kao SC; McCaughan B; Muljono A; Boyer M
    J Thorac Oncol; 2010 Mar; 5(3):405-6. PubMed ID: 20186029
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
    Tsao AS; Harun N; Lee JJ; Heymach J; Pisters K; Hong WK; Fujimoto J; Wistuba I
    Clin Lung Cancer; 2014 May; 15(3):197-201. PubMed ID: 24492162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
    Habib EE; Fahmy ES
    Clin Transl Oncol; 2013 Nov; 15(11):965-8. PubMed ID: 23408040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
    Hassan R; Kindler HL; Jahan T; Bazhenova L; Reck M; Thomas A; Pastan I; Parno J; O'Shannessy DJ; Fatato P; Maltzman JD; Wallin BA
    Clin Cancer Res; 2014 Dec; 20(23):5927-36. PubMed ID: 25231400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
    Ceresoli GL; Castagneto B; Zucali PA; Favaretto A; Mencoboni M; Grossi F; Cortinovis D; Del Conte G; Ceribelli A; Bearz A; Salamina S; De Vincenzo F; Cappuzzo F; Marangolo M; Torri V; Santoro A
    Br J Cancer; 2008 Jul; 99(1):51-6. PubMed ID: 18542071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.